Id love to see somebody like George W
Future studies whenever feasible might continue to explore heterogeneity of treatment effects of GLP1 receptor agonists or SGLT2 inhibitors, especially in clinically relevant subgroups, across BMI strata, and across age strata, which may suggest opportunities to optimize personalized dementia risk mitigation based on risk profiles
To view a copy of this licence, visit About this article Cite this article Schreier, P.C.F., Beyerle, P., Boulassel, S
If these principles are adhered to, there is no need to isolate HCV-positive patients or even to dialyze them separately on a dedicated machine
Everything below comes from either mouse studies at preclinical doses or uncontrolled community observations
16 Diabetes Control Complications Trial Research GroupNathanDMGenuthSLachinJClearyPCroffordOet al